Pharmaceuticals

Following a strategic merger and a $200M financing round, Yarrow Bioscience is advancing a novel drug for autoimmune thyroid disease. But can it disrupt a market dominated by incumbents?

A federal jury found investment firm RA Capital willfully misappropriated trade secrets from Yale, a stark reminder for investors of the risks of lax IP due diligence.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

Leveraging its global dominance in human medicine, Jiangxi Bio is entering the booming veterinary market with a new production line, a key move in its growth strategy.

With its $2.2B acquisition of Forte, argenx adds a first-in-class antibody, FB102, expanding its Vision 2030 strategy to redefine autoimmune care.

A positive EMA opinion for Minoryx's NEZGLYAL offers the first-ever drug therapy for a fatal childhood disease, highlighting a key regulatory pathway.

Ridgetech’s new leadership role in a key Chinese biomedical hub is no accident. It’s the result of turning strict drug traceability rules into a tech-driven advantage.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

Ipsen's BOLD trial for biliary atresia failed, a blow to families. But in the data from this setback lies a critical roadmap for future research.

Taiwan's Jyong Biotech touts a global licensing strategy for its BPH drug, but a closer look reveals significant clinical setbacks and financial pressures.

China SXT Pharma secured $9 million in a direct offering, but a catastrophic stock collapse reveals deep investor distrust in its survival strategy.

A Korean biotech is betting big on the U.S. market with its new GERD drug. A deal with manufacturer Bora Pharmaceuticals is the first step. Is it enough?

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.

Bio-Thera Solutions has begun a Phase 1 trial for BAT8013, a novel ADC targeting CD25 to deplete immunosuppressive cells in the tumor microenvironment.

Samsung Bioepis's latest report reveals a thriving biosimilar market, yet deep-seated policy debates over the 340B program threaten to disrupt growth.

Viking Therapeutics' appointment of digital health veteran Dorothy Gemmell signals a pivotal shift from lab to market in the crowded weight-loss field.

A new clinical trial combines two targeted therapies, offering potential hope for kidney cancer patients who have exhausted even the newest treatment options.

A new report reveals a seismic shift in drug manufacturing. Forget massive factories; the real power now lies with a handful of specialists building our medical future.

As the pet care market booms, Exubrion Therapeutics appoints a new CCO to expand its groundbreaking, single-injection arthritis treatment for dogs.